Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review

Authors
Roy L. J. van Wanrooij1,*, Michiel Bronswijk2,3,*, Rastislav Kunda4, Simon M. Everett5, Sundeep Lakhtakia6, Mihai Rimbas7,*, Tomas Hucl8, Abdenor Badaoui9, Ryan Law10, Paolo Giorgio Arcidiacono11, Alberto Larghi12, Marc Giovannini13, Mouen A. Khashab14, Kenneth F. Binmoeller15, Marc Barthet16, Manuel Pérez-Miranda17, Jeanin E. van Hooft18, Schalk W. van der Merwe3

Institutions
1 Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, AGEM Institute, Amsterdam, The Netherlands
2 Department of Gastroenterology and Hepatology, Imelda General Hospital, Bonheiden, Belgium
3 Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
4 Department of Surgery, Department of Gastroenterology and Hepatology, and Department of Advanced Interventional Endoscopy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
5 Department of Gastroenterology and Hepatology, Leeds Teaching Hospital NHS Trust, Leeds, UK
6 Department of Medical Gastroenterology, Asian Institute of Gastroenterology Hospitals, Gachibowli, Hyderabad, India
7 Gastroenterology Department, Colentina Clinical Hospital, Bucharest, Romania
8 Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
9 Department of Gastroenterology and Hepatology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
10 Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
11 Pancreatobiliary Endoscopy and Endosonography Division, IRCCS San Raffaele Scientific Institute, Milan, Italy
12 Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, and Center for Endoscopic Research Therapeutics and Training, Catholic University, Rome, Italy
13 Paoli-Calmettes Institute, Department of Gastrointestinal Disease, Marseille, France
14 Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, Maryland, USA
15 Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, California, USA
16 Department of Gastroenterology, Aix-Marseille Université, APHM, Hôpital Nord, Marseille, France
17 Gastroenterology Department, Hospital Universitario Rio Hortega, Valladolid, Spain
18 Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands

published online 2022

Bibliography
Endoscopy
DOI 10.1055/a-1738-6780
ISSN 0013-726X
© 2022. European Society of Gastrointestinal Endoscopy
All rights reserved.
This article is published by Thieme. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Corresponding author
Schalk W. van der Merwe, MD PhD, Department of Gastroenterology and Hepatology, University Hospital Leuven, Belgium
Schalk.vandermerwe@uzleuven.be

MAIN RECOMMENDATIONS
1 ESGE recommends a prolonged course of a prophylactic broad-spectrum antibiotic in patients with ascites who are undergoing therapeutic endoscopic ultrasound (EUS) procedures.
Strong recommendation, low quality evidence.

* Joint first authors

3 ESGE recommends EUS-guided pancreatic duct (PD) drainage should only be performed in high-volume expert centers, owing to the complexity of this technique and the high risk of adverse events. Strong recommendation, low quality evidence.

4 ESGE recommends a stepwise approach to EUS-guided PD drainage in patients with favorable anatomy, starting with rendezvous-assisted endoscopic retrograde pancreatography (RV-ERP), followed by antegrade or transmural drainage only when RV-ERP fails or is not feasible. Strong recommendation, low quality evidence.

5 ESGE suggests performing transduodenal EUS-guided gallbladder drainage with a lumen-apposing metal stent (LAMS), rather than using the transgastric route, as this may reduce the risk of stent dysfunction. Weak recommendation, low quality evidence.

6 ESGE recommends using saline instillation for small-bowel distension during EUS-guided gastroenterostomy. Strong recommendation, low quality evidence.

7 ESGE recommends the use of saline instillation with a 19G needle and an electrocautery-enhanced LAMS for EUS-directed transgastric endoscopic retrograde cholangiopancreatography (EDGE) procedures. Strong recommendation, low quality evidence.

8 ESGE recommends the use of either 15- or 20-mm LAMSs for EDGE, with a preference for 20-mm LAMSs when considering a same-session ERCP. Strong recommendation, low quality evidence.

**SOURCE AND SCOPE**

This Technical review complements the recent European Society of Gastrointestinal Endoscopy (ESGE) Guideline on therapeutic endoscopic ultrasound. The aim of this Technical review is to discuss the technical considerations of therapeutic endoscopic ultrasound and the management of adverse events. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to define the strength of recommendations and the quality of evidence.

1 Introduction

Endoscopic ultrasound (EUS) enables several therapeutic interventions in the pancreaticobiliary and gastrointestinal (GI) tract. A recent European Society of Gastrointestinal Endoscopy (ESGE) Guideline on therapeutic EUS provided an extensive overview of the indications and outcomes of these procedures [1]. EUS-guided management of fluid collections in acute necrotizing pancreatitis has been discussed in a previous ESGE guideline [2]. This review of the technical aspects of therapeutic EUS was commissioned by the ESGE to complement the guideline [1] focusing on procedural features and management of adverse events (AEs).

2 Methods

ESGE assigned this technical review and appointed a coordinating team (S.v.d.M., J.H., R.W., M.Br.). A team of experts across different domains of therapeutic EUS convened in May 2020. Two task force leaders (M.Ba. and M.P.M.) and their team members scrutinized the available literature for relevant articles pertaining to their fields of expertise. Topic-specific key questions were generated by each task force leader. Searches were performed using Medline (via Pubmed) and the Cochrane library up to June 2021. The level of evidence for each question was scored according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system into high, moderate, low, or very low [3]. Recommendations were drafted and the strength of each was determined as strong or weak. Various web meetings were held to discuss and resolve issues, and formulate recommendations.

In October 2021, a final draft was sent to all group members for review. After all authors approved the final version, the manuscript was submitted to Endoscopy for publication. ESGE acknowledges that the field of therapeutic EUS is rapidly changing and that continued efforts will be required in the future to update and maintain these guidelines as more high-quality published data are generated.

3 General precautions and principles for therapeutic EUS

3.1 Key question1: What are the general pre- and post-procedural precautions that should be taken when performing therapeutic EUS?

**RECOMMENDATION**

ESGE recommends therapeutic EUS procedures should be performed by endoscopists with adequate training and experience, at centers where interventional radiology and hepatopancreaticobiliary surgical expertise are available. Strong recommendation, low quality evidence.
3.1.1 General considerations
Patients considered for therapeutic EUS procedures should be carefully selected based on criteria provided in the ESGE guideline [1]. In some settings, multidisciplinary discussions may be applicable before embarking on these procedures. Patients should be made aware of specific procedure-related risks and potential alternative therapeutic strategies when providing informed consent.

The endoscopist performing the procedure should have adequate experience in therapeutic EUS and endoscopic retrograde cholangiopancreatography (ERCP), as the level of the endoscopist’s experience determines procedural outcome [4–9]. In addition, the availability of hepatopancreaticobiliary surgical and interventional radiological expertise is recommended in centers where therapeutic EUS procedures are performed, in case AEs occur [10, 11].

3.1.2 Preprocedural considerations

**RECOMMENDATIONS**

ESGE recommends temporary discontinuation of anticoagulant therapy before embarking on therapeutic EUS procedures.

Strong recommendation, low quality evidence.

ESGE recommends temporarily switching dual antiplatelet therapy to aspirin monotherapy, whenever possible, before embarking on therapeutic EUS procedures.

Weak recommendation, low quality evidence.

ESGE suggests prophylactic administration of an intravenous broad-spectrum antibiotic in all patients undergoing therapeutic EUS procedures.

Weak recommendation, low quality evidence.

ESGE recommends a prolonged course of a prophylactic broad-spectrum antibiotic in patients with ascites who are undergoing therapeutic EUS procedures.

Strong recommendation, low quality evidence.

According to the recent ESGE guideline on antiplatelet or anticoagulation therapy use in endoscopy, therapeutic EUS procedures are classified “high risk” [12]. In accordance with this guideline, before embarking on a therapeutic EUS procedure, anticoagulant therapy should be temporarily discontinued, while dual antiplatelet therapy should be converted to aspirin monotherapy where possible. However, small series have described the successful use of fully covered self-expandable metal stents (FCSEMSs) or lumen-apposing metal stents (LAMSs) in bile duct and gallbladder drainage procedures in patients on anticoagulant therapy and/or antiplatelet therapy [13, 14]. The inherent radial expansion forces of these stents will likely contribute to a reduced risk of periprocedural bleeding by providing a tamponade effect on the intraparietal blood vessels [13, 15]. Even though these data are encouraging, more high quality evidence is needed before the current ESGE recommendations can be reconsidered.

Prophylactic administration of broad-spectrum antibiotics may prevent infectious AEs following a therapeutic EUS procedure. There are currently no data available that have reported prophylactic antibiotics to be beneficial in therapeutic EUS. Until more data become available, it is recommended that a single dose of intravenous antibiotics is administered when a transmural therapeutic procedure is performed, analogous to surgical and interventional radiology protocols [16, 17]. Longer administration periods may be required in the presence of ascites, in immunocompromised patients, or in those where adequate biliary drainage was not achieved.
A large volume of ascites may increase the difficulty of therapeutic EUS as it may prevent access to the target organ with a fine-needle aspiration (FNA) needle or stent catheter, and may lead to stent migration and cause bacterial peritonitis [18, 19]. When a therapeutic EUS procedure is still deemed necessary, a preprocedural paracentesis may be helpful before embarking on such a procedure.

3.1.3 Periprocedural considerations
Adequate support to protect the patient’s airway and prevent aspiration is regarded as indispensable during therapeutic EUS. Many centers perform therapeutic EUS exclusively in intubated and mechanically ventilated patients under general anesthesia, whilst conscious/deep sedation is used in other experienced centers without compromising safety outcomes. Procedures should ideally be performed in a fluoroscopy room, where imaging may be especially helpful in providing guidance if endoscopic salvage procedures are required.

3.1.4 Post-procedural considerations
The duration of post-procedural hospitalization for observation should be based on a patient’s characteristics, such as medical co-morbidities, and procedural aspects, including a higher risk and/or greater difficulty of the procedure. Imaging studies (e.g. CT scan) should be performed when a post-procedural AE is suspected.

3.2 Key question 2: What are the general technical principles in therapeutic EUS?

3.2.1 Which interventional therapeutic techniques are used?
Therapeutic EUS uses various different approaches to obtain access to the target structure. The “rendezvous” technique (or “EUS-assisted” procedure) refers to the use of EUS to provide ductal access to facilitate subsequent ERCP, and is therefore considered an “indirect technique.” “EUS-guided” interventions refer to procedures performed under EUS guidance and therefore considered “direct techniques.”

Direct EUS-guided interventions typically involve transmural stent placement. These procedures can either be performed by a multistep approach, where access to the target organ is obtained using an FNA needle and guidewire that allows over-the-wire insertion of various tools and placement of a stent, or alternatively, an all-in-one approach using an electrocautery-enhanced lumen-apposing metal stent (EC-LAMS), which permits “free-hand” insertion of this device into the target structure without prior placement of a guidewire. The latter technique obviates the need for multiple accessory exchanges, thereby potentially reducing the risk of procedural failure and AEs. Some EUS-guided interventions may be further assisted by the use of additional accessories such as catheters (i.e. nasobiliary) or balloons.

When the target structures of interventional EUS are the pancreatic and biliary ducts, direct techniques may allow antegrade, as well as transmural, drainage. In addition to retrograde procedures by ERCP, antegrade procedures reinstate the normal flow direction by bridging a stenosis and/or papilla, whereas transmural drainage redirects flow away from the normal route by creating a new anastomosis.

3.2.2 General technical principles in EUS-assisted and EUS-guided techniques

**RECOMMENDATIONS**
ESGE suggests a fistulous tract be created using a 6-Fr cystotome or alternatively by mechanical dilation. Weak recommendation, low quality evidence.

ESGE recommends that endoscopists should undergo rigorous training in lumen-apposing metal stent placement and the management of adverse events before undertaking therapeutic EUS procedures using these devices. Strong recommendation, low quality evidence.

During EUS-assisted rendezvous (EUS-RV), access to the target structure is obtained using an EUS-FNA needle (most commonly a 19 G needle as it accommodates guidewires up to 0.035-inch diameter). Before the injection of contrast, adequate positioning of the needle tip inside the target lumen should be confirmed by EUS. When a bile duct is punctured, aspiration of bile may further confirm proper needle positioning. Correct needle placement is followed by contrast injection to depict the anatomy of the target structure (pancreatic or biliary duct, gallbladder, small intestine, or stomach). The needle is ideally rinsed with saline every time contrast is injected, to prevent subsequent difficulties with guidewire advancement due to the adhesive properties of the contrast medium. Because of its stiffness, some endoscopists favor the use of a 0.035-inch guidewire of 450 cm in length with an 19 G FNA needle. However, this may shear easily, hampering wire manipulation and leaving residual foreign material behind in the target when a beveled needle is being used. In order to overcome shearing, an atraumatic “access” needle may be used. Alternatively, a 19 G FNA needle may be combined with a thinner 0.025-inch monofilament guidewire that is less prone to shearing [20].

When the diameter of the target organ is limited, such as for biliary access, a thinner 22 G needle may be preferred over a 19 G needle, which can accommodate small 0.021-inch or 0.018-inch guidewires [21]. However, subsequent device advancement can be considerably more challenging when using small caliber guidewires. In addition, small caliber guidewires are not insulated against electrical current and are therefore not compatible with the concomitant use of cautery-based devices such as cystotomes.

Guidewire manipulation in EUS-guided biliary drainage (EUS-BD) is critical, especially in EUS-RV and antegrade transpapillary (or transanastomotic) stent placement, as successful passage of the stricture and/or papilla is required to complete the procedure. If the direction of the wire is undesirable, a wire with an angulated tip or a torque device may aid in steering it across a stricture. Recently, a steerable access needle has
been developed, which facilitates guidewire advancement in the desired direction and appears to be especially useful in EUS-RV, where cystotomes or sphincterotomes are not commonly used [22, 23].

In EUS-RV, the wire is advanced via the pancreatic or biliary duct into the duodenum, after which the echoendoscope is removed and exchanged for a duodenoscope, while leaving the guidewire in place for subsequent ERCP. In EUS-guided procedures, successful guidewire placement is followed by the creation of a fistulous tract, which enables subsequent transmural or antegrade stent placement.

Fistula tract dilation can be achieved using mechanical or cautery devices. For mechanical dilation, a tapered dilating catheter or a hydrostatic balloon may be used [20, 24]. Mechanical dilation limits damage to surrounding structures. These devices are however sometimes difficult to insert across the puncture tract, which may then compromise the stability of the endoscope.

Cautery devices enable the application of pure cutting current to overcome this problem. A coaxial cystotome is preferred over a needle-knife because the latter has been identified as a risk factor for AEs in EUS-BD [25]. More specifically, the 6-Fr cystotome is an ideal accessory that creates a tract that allows the introduction of various tools and stent-introducing catheters, without leading to clinically significant bile leakage or capsulorperitoneum/pneumoperitoneum if the procedure should fail [26]. The 6-Fr cystotome is however not universally available and, in this specific context, mechanical dilation is preferred over the use of a 10–Fr cystotome, as such a large caliber device may lead to significantly more thermal injury to the surrounding structures, potentially resulting in leakage of GI contents and free air if the procedure should fail.

The development of EC-LAMSs has enabled one-step direct access and drainage of the common bile duct and gallbladder; they are also used to create anastomoses in the GI tract. The development of EC-LAMSs has revolutionized the field of therapeutic EUS owing to their following unique characteristics. First, the all-in-one device obviates the need to use multiple tools, avoiding device exchanges that could potentially lead to procedural failure and AEs. Second, their dumbbell shape prevents migration and fuses the individual wall layers together, forming a mature anastomosis. Third, LAMSs are fully covered and leakage of bile or gastric acid intra-abdominally is rare. This characteristic also facilitates stent removal when indicated [27]. EC-LAMSs are available in various sizes in order to meet specific procedural needs (Table 1).

Initially, EC-LAMSs were introduced over a guidewire, but this technique has fallen out of favor as the guidewire may actually push the target structure away from the GI wall, leading to stent maldeployment [28]. Therefore, EC-LAMSs are preferably introduced directly into the target structure using pure cutting current, referred to as the “free-hand technique.” An endosonographic window where the target organ is within 10–20 mm from the GI wall (depending on the stent design), without intervening large blood vessels or ascites, should be sought. Placement of the LAMS is performed by applying pure cutting current (Autocut 100–150 W, effect 3–5) just before advancing the cautery tip to ensure rapid bridging of the GI layers into the target structure and to lessen coagulation artefacts that may obscure the view of the device. When the electrocautery tip is in position within the target structure, the distal flange of the LAMS can be deployed under endosonographic control. When adequately deployed, the distal flange is pulled towards the GI wall until its shape changes from flat to oval, indicating adequate approximation of the layers to allow for safe release of the proximal flange inside the GI lumen. More control over the stent position can be achieved by the proximal flange of the LAMS being deployed inside the working channel of the echoendoscope and slowly expelled under endoscopic control [29].

**Table 1** The currently available electrocautery-enhanced lumen-apposing metals stents.

<table>
<thead>
<tr>
<th>Stent</th>
<th>Manufacturer</th>
<th>Stent measurements, mm</th>
<th>Delivery system</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Internal diameter</td>
<td>Flange diameter</td>
</tr>
<tr>
<td>Hot Axios</td>
<td>Boston Scientific, Marlborough,</td>
<td>6</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Massachusetts, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20</td>
<td>29</td>
</tr>
<tr>
<td>Hot Spaxus</td>
<td>Taewoon Medical, Gyeonggi-do,</td>
<td>8</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>South Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16</td>
<td>31</td>
</tr>
</tbody>
</table>

* The saddle length of the Hot Spaxus stent is variable between 7 and 20 mm.
After successful placement of LAMSs, adequate stent position should be confirmed by either endoscopic confirmation of recognizable fluid (e.g., bile, or blue-dyed liquid in the case of EUS-GE) being released from the stent, or contrast injection through the stent, which will fluoroscopically confirm correct placement within the target structure. It is of utmost importance to immediately recognize stent maldeployment during the procedure, so that adequate salvage measures may be undertaken as described in the sections below. Therefore, adequate training in LAMS placement and the management of AEs should be a prerequisite before performing therapeutic EUS procedures.

3.2.3 When should a therapeutic EUS procedure be aborted?

**RECOMMENDATION**

ESGE recommends discontinuation of the procedure when tumor infiltration, significant ascites, or large intervening blood vessels are identified at the desired puncture site of the gastrointestinal wall or target organ.

Strong recommendation, low quality evidence.

Certain findings during the procedure may prevent successful completion and will require the endoscopist to abort. These include identifying infiltrating tumor or large blood vessels in the GI wall or target organ along the trajectory of the desired puncture site. Under these circumstances, the procedure should be aborted owing to an increased risk of stent maldeployment and bleeding [20]. The same risks apply, when only mildly dilated, a thinner 22 G needle may be preferred [21]. After adequate needle positioning has been confirmed, a cholangiogram is performed. The guidewire should then be manipulated across the papilla into the duodenum where it is coiled. At this point, the echoendoscope is carefully removed leaving the guidewire behind. A duodenoscope is then introduced alongside the guidewire and advanced up to the level of the papilla. A sphincterotome can then be advanced directly adjacent to the guidewire where it protrudes from the papilla, which may allow CBD cannulation. Alternatively, the guidewire protruding from the papilla and coiled in the duodenum may be grasped using a forceps or snare and pulled through the working channel of the duodenoscope, over which a sphincterotome may then be advanced into the CBD. During this step, care should be taken to grasp an adequate length of the guidewire, in order to prevent wire fracture near its floppy tip.

4.1.2 EUS-guided antegrade stenting

For EUS-guided antegrade stenting, the echoendoscope is positioned in the stomach and directed so that the intrahepatic bile ducts of the left liver lobe can be visualized (Fig. 1b), whilst at the same time avoiding a transesophageal puncture, which may carry a higher risk of AEs [32]. The intrahepatic bile ducts are punctured preferably at a depth of 2.5–3 cm, so that the surrounding liver parenchyma will contain any potential bile leakage [33]. A cholangiogram will provide a “roadmap” that will aid in guidewire passage across the stricture and/or papilla. When the guidewire is safely coiled up within the small intestine or positioned deep into the intrahepatic bile ducts, a fistulous tract can be created using a cystotome or dilation balloon, which allows the introduction of the accessories that will aid in performing sphincteroplasty, stricture dilation, brush cytology, stone removal, and/or SEMS placement.

Adequate dilation of a distal stricture should be considered before placement of a transpapillary stent as the direction of the stent catheter away from the papilla can lead to loss of stiffness and ability to advance the stent catheter. When intraductal pressure is relieved from the biliary system by downstream stent placement, the risk of bile leakage from the puncture tract is negligible. Conversely, when stent placement across the obstruction fails, the risk of bile leakage is of concern and warrants salvage biliary drainage, either with EUS-guided hepaticogastrostomy (EUS-HGS) or percutaneous transhepatic biliary duct drainage (PTBD).
In EUS-guided choledochoduodenostomy (EUS-CDS), a biliodigestive anastomosis is created with either a biliary metal stent or LAMS (Fig. 1c). The distal CBD is visualized from the duodenal bulb, and an optimal window for EUS-CDS is sought, avoiding intervening tumor tissue. The CBD is punctured, a cholangiogram performed, and a guidewire placed, facilitating dilation of the tract for stent placement.

Plastic stents, uncovered and covered biliary metal stents, and LAMSs have all been used in performing EUS-CDS (Table 2). Plastic stents and uncovered SEMSs (USEMSs) may however fail to adequately seal the biliodigestive anastomosis and may increase the risk of bile leakage [34]. Studies using FCSEMSs, usually 6 cm in length, have reported satisfactory outcomes. Partially covered SEMSs (PCSEMSs) have also been used, where anchoring fins and minimal foreshortening of the stent counteract stent migration [35–37].

More recently, all-in-one EC-LAMSs have enabled the performance of direct EUS-CDS, eliminating the need for accessory exchanges, theoretically reducing the risk of procedural failure and AEs. Only small caliber LAMSs should be used for EUS-CDS regardless of the diameter of the CBD. EUS-CDS will significantly reduce the diameter of the CBD and the use of larger caliber LAMSs may result in damage to the CBD wall. Data from one retrospective comparative study and a meta-analysis comparing outcomes with LAMSs versus biliary SEMSs for EUS-CDS have failed however to show significant differences between these two techniques [35, 38].

For EUS-CDS using an EC-LAMS, the free-hand technique allows direct access to the CBD. EUS-CDS using a LAMS may be challenging in small diameter CBDs (<12 mm), as deployment of the distal flange of the stent inside the duct may be difficult. Two procedural adjustments that may be considered to overcome this limitation are: (i) performing LAMS deployment in a stepwise manner, with the distal flange being opened into the duct in incremental steps; (ii) advancing a guidewire through the LAMS-introducing catheter, which will allow the operator to direct the catheter towards the liver hilum and open the stent flange perpendicular to the main axis of the CBD.

RECOMMENDATION

ESGE recommends the placement of partially or fully covered self-expandable metal stents or small caliber lumen-apposing metal stents during EUS-guided choledochoduodenostomy.

Strong recommendation, moderate quality evidence.

Fig. 1a–c Illustrations of therapeutic endoscopic ultrasound (EUS) interventions of the pancreaticobiliary and gastrointestinal tract showing: a EUS-assisted rendezvous (biliary); b EUS-guided antegrade stenting; c EUS-guided choledochoduodenostomy. Source: Martha Meisen.
4.1.4 EUS-guided hepaticogastrostomy

During EUS-HGS, the dilated intrahepatic bile ducts are visualized from the left liver lobe (Fig. 1d). The position of the tip of the echoendoscope should be located in the stomach to prevent inadvertent placement of a SEMS into the esophagus, which may result in dysphagia and vomiting. The basic steps are similar to those for EUS-guided antegrade stent placement. Access is secured by placement of a guidewire through a 19G needle, deep into the biliary system, over which accessories can be advanced to permit deployment of a stent between the dilated left ductal system and the stomach.

Various types of stents have been used in EUS-HGS. Double-pigtail stents are difficult to place and USEMSs carry an unacceptably high risk of bile leakage. A purposely developed single-pigtail stent for HGS is available in some countries, where excellent outcomes have been reported using these stents [39, 40]. On the other hand, FCSEMSs may obstruct distal bile duct branches and cause cholangitis, but their removability after fistulous tract maturation makes them especially suitable for benign indications. In this way EUS-HGS may serve as a “portal” to the biliary system, allowing direct cholangioscopy-guided lithotripsy, as well as the evaluation of strictures in surgically altered anatomy [41–44].

During EUS-HGS, the dilated intrahepatic bile ducts are visualized from the left liver lobe (Fig. 1d). The position of the tip of the echoendoscope should be located in the stomach to prevent inadvertent placement of a SEMS into the esophagus, which may result in dysphagia and vomiting. The basic steps are similar to those for EUS-guided antegrade stent placement. Access is secured by placement of a guidewire through a 19G needle, deep into the biliary system, over which accessories can be advanced to permit deployment of a stent between the dilated left ductal system and the stomach.

Various types of stents have been used in EUS-HGS. Double-pigtail stents are difficult to place and USEMSs carry an unacceptably high risk of bile leakage. A purposely developed single-pigtail stent for HGS is available in some countries, where excellent outcomes have been reported using these stents [39, 40]. On the other hand, FCSEMSs may obstruct distal bile duct branches and cause cholangitis, but their removability after fistulous tract maturation makes them especially suitable for benign indications. In this way EUS-HGS may serve as a “portal” to the biliary system, allowing direct cholangioscopy-guided lithotripsy, as well as the evaluation of strictures in surgically altered anatomy [41–44].

Standard FCSEMSs appear less suited for long-term drainage because stent dysfunction and dislocation, which may be more common with certain FCSEMS types, may occur in up to 50% of cases [45]. A hybrid stent has been developed with the aim of improving the outcomes of long-term drainage in malignant settings. It is made of an uncovered (±30%) intraductal portion that prevents bile duct branch obstruction, while the remaining part is fully covered to prevent bile leakage at the anastomotic transparietal site [46].

**Table 2** Stents advised for each therapeutic endoscopic ultrasound (EUS) procedure.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Plastic stents</th>
<th>Biliary self-expandable metal stents</th>
<th>Lumen-apposing metal stent*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUS-CDS</td>
<td>Not advised for primary drainage</td>
<td>Fully covered</td>
<td>Hot Axios</td>
</tr>
<tr>
<td></td>
<td></td>
<td>length: 6 cm</td>
<td>6 × 8 mm, 8 × 8 mm, 10 × 10 mm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>diameter: 8–10 mm</td>
<td>Hot Spaxus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 × 20/7 mm</td>
</tr>
<tr>
<td>EUS-HGS</td>
<td>Not advised for primary drainage</td>
<td>Fully covered</td>
<td>Not advised for primary drainage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>length: 8–10 cm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>diameter: 8–10 mm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Partially covered</td>
<td>Not advised for primary drainage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>length: 8–10 cm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(uncovered 3 cm, covered 5–7 cm)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>diameter: 8–10 mm</td>
<td></td>
</tr>
<tr>
<td>EUS-guided PD drainage (antegrade)</td>
<td>Straight or double pigtail</td>
<td>Not advised for primary drainage</td>
<td>Not advised for primary drainage</td>
</tr>
<tr>
<td></td>
<td>5, 7, 8.5, and 10 Fr</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>length: 7–20 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS-GBD</td>
<td>Not advised for primary drainage</td>
<td>Not advised for primary drainage</td>
<td>Hot Axios</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 × 10 mm, 15 × 10 mm</td>
<td>Hot Spaxus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 × 20/7 mm, 10 × 20/7 mm</td>
<td></td>
</tr>
<tr>
<td>EUS-GE</td>
<td>Not advised for primary drainage</td>
<td>Not advised for primary drainage</td>
<td>Hot Axios</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 × 10 mm, 20 × 10 mm</td>
<td>Hot Spaxus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16 × 20/7 mm</td>
<td></td>
</tr>
</tbody>
</table>

EUS-CDS, EUS-guided cholecdochoodenostomy; EUS-HGS, EUS-guided hepaticogastrostomy; PD, pancreatic duct; EUS-GBD, EUS-guided gallbladder drainage; EUS-GE, EUS-guided gastroenterostomy.

* Lumen-apposing metal stents (LAMSs) detailed here are all electrocautery-enhanced as their all-in-one design renders them ideal for therapeutic EUS procedures. LAMSs without the electrocautery-enhanced delivery system (Axios, Spaxus) are also available in various sizes, but would require multiple accessory exchanges.

**RECOMMENDATIONS**

ESGE recommends placement of partially or fully covered self-expandable metal stents (SEMSs) during EUS-guided hepaticogastrostomy for biliary drainage in malignant disease.

Strong recommendation, moderate quality evidence.

ESGE recommends temporary placement of fully covered SEMSs during EUS-guided hepaticogastrostomy for biliary drainage in benign disease.

Strong recommendation, low quality evidence.
When EUS-HGS is performed, it is important to deploy the stent inside the working channel of the scope, whilst simultaneously retracting the scope so that at least 2–3 cm of the stent protrudes into the gastric lumen to prevent stent migration [47, 48]. In some instances, when the right and left liver lobes are non-communicating and are disconnected by tumor, it may be possible to place a bridging stent to reconnect both systems to optimize biliary drainage [49, 50].

4.1.5 EUS-guided hepaticoduodenostomy

**RECOMMENDATION**

ESGE recommends EUS-guided hepaticoduodenostomy be performed only at expert centers and after careful consideration of all therapeutic options.

Strong recommendation, low quality evidence.

The right liver lobe can only be partially visualized via the duodenal bulb in the long position. Similarly to EUS-HGS, the bile duct is punctured with a 19G needle and a cholangiogram performed. After a guidewire has been advanced into the bile duct, a tract is created using a 6-Fr cystotome or dilation balloon. An FCSEMS is placed with the proximal tip in the dilated bile duct and the distal tip about 2–3 cm inside the duodenum.

There is currently only very limited experience with this technically demanding technique; for this indication PTBD remains the gold standard [51, 52].

4.2 Key question 4: What adverse events may occur when EUS-BD is performed and how should these be managed?

4.2.1 Stent maldeployment and perforation

**RECOMMENDATION**

ESGE recommends endoscopic stent-in-stent therapy when maldeployment occurs during EUS-guided hepaticogastroduodenostomy and, if this is not feasible, that percutaneous transhepatic biliary drainage or emergency salvage surgery should be considered.

Strong recommendation, low quality evidence.

Stent maldeployment may lead to bile leakage, which may increase the distance between the duodenum and CBD, preventing a successful second attempt at LAMS placement. In this setting, the CBD defect may be closed by performing EUS-RV with placement of an FCSEMS by ERCP, or alternatively EUS-guided antegrade stent placement may be performed followed...
by LAMS removal and endoscopic closure of the duodenal defect with the most appropriate clip [53].

EUS-BD performed in a small diameter CBD increases the risk of accidental perforation of the portal vein, which can induce substantial blood loss via the LAMS into the duodenum. The same salvage procedure as described above can ensure resolution of both the CBD and portal vein defects, although hospitalization and close monitoring will be required in such instances, given the potential risk of severe bleeding [54].

Interventional radiology with PTBD should be used if endoscopic salvage therapy fails. In EUS-CDS, this is especially warranted for all punctures crossing the peritoneal cavity. Punctures in the retroperitoneal portion of duodenum and distal CBD may be managed conservatively, as these can usually be resolved by same-session EUS-guided CBD drainage, targeting an area adjacent to the site of the failed attempt.

Stent maldeployment in EUS-HGS usually occurs when the proximal end of the stent is deployed inside the peritoneal cavity, instead of in the gastric lumen, leading to biliary peritonitis that may potentially be fatal [55]. Inadequate stent placement may become apparent when the “candy sign” is observed on fluoroscopy, whereby the liver capsule and gastric wall are not adjacent to each other and appear as two distinct indentations [48]. This can be prevented by applying tension on the delivery catheter and retracting the echoendoscope in a stepwise manner to ensure that the proximal end of the stent opens in the stomach during deployment.

When the proximal end of the stent is still visible in the gastric wall, it can be pulled towards the gastric lumen using a grasping forceps before an additional stent-in-stent is placed to anchor the primary stent and prevent migration [56, 57]. If the stent is completely outside the gastric wall but the guidewire is still in place, one may attempt to release a second FCSEMS over the wire in order to bridge the maldeployed stent to the stomach [58]. If this is not possible, access to the dislocated stent can be regained by puncturing it under EUS guidance, followed by guidewire advancement into the liver and placement of a second bridging stent [59]. When these procedures fail, emergency salvage surgery, with repositioning of the stent may be indicated [58]. The principal objective of all salvage procedures should be to achieve bile duct drainage and to secure closure of the puncture defects on both sides of adjacent organs, either by means of surgical drainage or PTBD in order to relieve intraductal pressure, thereby reducing the risk of delayed bile leakage.

Bleeding may occur during the procedure or may be delayed, but in most cases conservative treatment and observation will suffice. Rarely, bleeding can be severe or persistent and interventional radiology management may be required to manage an arteriobiliary fistula.

4.2.2 Endoscopic treatment of long-term adverse events

**RECOMMENDATION**

ESGE recommends placement of a stent through the metal stent when EUS-guided choledochoduodenostomy or EUS-guided hepaticogastrostomy is complicated by stent occlusion.

Strong recommendation, low quality evidence.

EUS-CDS stents may become occluded by food remnants or sludge, or due to compression of the contralateral wall of the CBD, especially when a large diameter LAMS has been used [60, 61]. LAMSs placed for EUS-CDS have been sporadically reported to migrate, though without bile leakage, which implies that the dislocation has occurred after the fistulous tract had matured [62, 63]. When the fistula is still open, a new stent can be placed. Double-pigtail stent-in-stent procedures may be placed through the metal stent to maintain stent patency [60, 61]. Prophylactic DPPS placement through a LAMS was however not found to improve any procedural outcome in a multicenter retrospective cohort study [64].

Stent occlusion in EUS-HGS can be treated by placing DPPSs or SEMSs coaxially through the occluded metal stent. Stent ingrowth or overgrowth can be addressed by the use of intraductal radiofrequency ablation to regain stent patency. Cannulation of the occluded metal stent can sometimes be challenging if a relatively long portion of the metal stent protrudes into the stomach. In these cases, a small incision made with a needle-knife along the side of the stent, or trimming by argon plasma coagulation (APC) may provide easy access into the stent lumen, which then facilitates further interventions, such as guidewire passage and stent-in-stent placement [65, 66].

4.3 Key question 5: How should EUS-guided PD drainage be performed?

4.3.1 General principles of EUS-guided PD

**RECOMMENDATION**

ESGE recommends EUS-guided pancreatic duct drainage should only be performed at high volume expert centers, owing to the complexity of this technique and the high risk of adverse events.

Strong recommendation, low quality evidence.

Chronic pancreatitis-related pain may be due to ductal hypertension caused by obstruction of the main pancreatic duct (MPD) by stones, congenital anomalies, and/or strictures. Ductal decompression represents the main treatment modality and can be provided by endoscopic retrograde pancreatography (ERP) or surgical decompression [67]. In 2007, a randomized comparison of these two techniques showed superior efficacy of surgical drainage, with technical success of ERP.
achieved in only 53% of cases at an academic expert setting [67]. Surgically altered anatomy, duct disruption, large stones, or tight strictures are all typical causative features leading to ERP failure.

EUS-guided PD drainage facilitates access to the MPD, thereby leading to EUS-guided PD drainage becoming an invaluable rescue procedure when ERP fails [68–70]. EUS-guided PD drainage procedures are however technically demanding and lead to high morbidity in comparison to other therapeutic EUS procedures, and should only be performed in high volume expert centers. The (contra)indications, comparisons with alternatives, and potential AEs have been discussed in the ESGE guideline [1]. The aim of the following sections is to provide guidance on how EUS-guided PD drainage should be performed.

### 4.3.3 EUS-guided PD drainage

**RECOMMENDATION**

ESGE recommends the use of rectal nonsteroidal anti-inflammatory drugs in patients undergoing EUS-guided pancreatic duct drainage.

Strong recommendation, low quality evidence.

EUS-guided PD drainage can be done by either EUS-assisted (i.e. rendezvous-assisted ERP [RV-ERP]) or EUS-guided antegrade or transmural approaches. Although no formal comparison exists between these three approaches, it is generally accepted that RV-ERP may hold significant advantages over antegrade or transmural drainage with regards to safety and efficacy [69, 71–73]. The latter techniques are therefore only recommended in patients where RV-ERP fails or is not technically feasible [1, 68, 72].

Patients undergoing EUS-guided PD drainage may benefit from rectal nonsteroidal anti-inflammatory prophylaxis and broad-spectrum antibiotics [69, 73–76], although this has not been systematically studied.

#### 4.3.2 Rendezvous-assisted ERP

After the PD has been accessed with a preflushed 19G or 22G FNA needle under EUS guidance, the anatomy is defined fluoroscopically by contrast injection. A 0.035/0.025-inch or 0.021/0.018-inch guidewire is then advanced into the PD (Fig. 1e). The use of 22G needles and smaller caliber guidewires is generally discouraged as these wires may not be sufficiently rigid to allow for the advancement of dilation balloons, rigid dilators, and stents [68, 75, 77]. The main goal is to advance the guidewire deep into the duodenum, to achieve a stable transpapillary or transanastomotic platform, and prevent guidewire dislocation while the echoendoscope is exchanged for the duodenoscope. During the process of guidewire manipulation, it can be extremely challenging to advance the guidewire beyond stones and/or strictures. If attempts are unsuccessful, despite extensive guidewire manipulation, a fistulous tract can be created using a 6-Fr cystotome or mechanical dilation. This will allow instruments, such as the cystotome or an ERCP catheter, to be advanced into the PD, which will provide a more stable platform for guidewire manipulation. If the guidewire still cannot be advanced across the stricture or beyond the stone with the aid of the cystotome, this tract may immediately facilitate transmural PD drainage to the stomach or duodenal bulb.

In patients with surgically altered anatomy, an inaccessible papilla, or where RV-ERP has failed, EUS-guided PD drainage should be considered. Variations of this technique depend on the puncture site and whether a stent will eventually be placed transmurally or in antegrade fashion across an anastomosis or papilla. Variations include pancreaticogastrostomy (Fig. 1f), pancreaticoenterostomy, gastropancreaticoenterostomy (also called “ring drainage”), and pancreaticobulbostomy [71]. The MPD diameter should at least be 4 mm, as this increases the technical success rate and decreases morbidity.

When previous RV-ERP has been attempted, the cystotome tract can be used to perform EUS-guided PD drainage. Various authors have however suggested first attempting non-cautery-assisted tract dilation with rigid dilators or 4–6-mm balloons to prevent potential thermal injury to the pancreas [69, 74, 78]. Following tract preparation, straight plastic stents (5–10 Fr) are inserted, depending on the MPD caliber, and may be directed towards the pancreatic tail or head. FCSEMIs have also been successfully used, although only in a small number of patients [79]. Transmural drainage by transgastric or transenteric stent placement will create a pancreaticogastrostomy, pancreaticoenterostomy, or pancreaticobulbostomy, depending on the scope position, anatomy, and needle access.

In gastropancreaticoenterostomy or “ring drainage,” a pancreaticogastrostomy and pancreaticoenterostomy are created simultaneously by passing the distal end of the DPPS through the papilla or anastomosis into the small bowel and deploying the proximal end into the gastric lumen, creating a secure gastropancreaticoenterostomy [74]. For this technique, transpapillary or transanastomotic access is required, but it carries significant advantages compared with the classic pancreaticogastrostomy or pancreaticoenterostomy techniques owing to the double-sided drainage and secure DPPS placement, which prevents migration [69].
4.4 Key question 6: What are the adverse events and possible rescue procedures in EUS-guided PD drainage?

4.4.1 Intraprocedural challenges and rescue procedures

Accessing the MPD with a 19G-needle can be challenging owing to significant pancreatic fibrosis and/or calcified parenchyma, which can complicate smooth needle insertion, tract dilation, and stent placement [74]. In such patients, or where the MPD is only minimally dilated, a 22G FNA needle may prove more successful in accessing the MPD; however, it only allows insertion of a 0.018-inch guidewire, which is often inadequate, as described above for other techniques [68,80].

Guidewire access may be extremely difficult because of large MPD obstructing stones. Preprocedural stone fragmentation by extracorporeal shockwave lithotripsy may potentially improve the technical and clinical success rates of RV-ERP [81,82]. The most crucial steps during RV-ERP require successful advancement of the guidewire across strictures/stones deep into the duodenum, followed by careful exchange of the echoendoscope for a duodenoscope, avoiding guidewire dislocation.

For EUS-guided PD drainage specifically, the difficulty lies in the ability to dilate the transmural tract sufficiently to insert a stent deep enough into the MPD to prevent stent dislocation [69,74]. In the unfortunate situation where the plastic stent dislocates beyond the gastric wall during EUS-guided PD drainage, a snare over the guidewire or a digital cholangioscope may be used in an attempt to recover the stent. If the MPD is successfully punctured but subsequent drainage fails, the risk for the development of peripancreatic collections increases and may become evident only over the ensuing days. These patients should be observed more closely, the antibiotic course extended, and transgastric drainage considered, especially if these collections become symptomatic or infected.

4.4.2 Endoscopic treatment of long-term adverse events

Most AEs are known to occur immediately following unsuccessful drainage, while limited long-term safety data are available [63]. In RV-ERP, classic stent exchanges are required with re-interventions scheduled every 3–6 months [81]. Long-term AEs in this group are therefore related to ERP only. Antegrade approaches, such as pancreaticogastrostomy and pancreatico-bulbostomy, are known to exhibit a significant risk of stent dysfunction over time owing to obstruction and/or migration [78]. In one of the initial retrospective studies reporting EUS-guided PD drainage (n = 36), clinical success was obtained in 69.4% of patients, although in 55% stent dysfunction occurred after a mean follow-up of 14 months [73]. Stent exchange management among experts varies from scheduled exchanges every 6 months to exchanges “on-demand” when symptoms recur. Migration can be problematic in these patients, as the MPD diameter will have decreased, complicating repeat EUS-guided PD drainage. In this population, few further therapeutic options currently exist, given the low technical success associated with ERP and the difficulties associated with rescue surgery.

5.1 Key question 7: How should EUS-GBD be performed?

5.1.1 LAMS placement

**RECOMMENDATIONS**

ESGE suggests the use of an electrocautery-enhanced lumen-apposing metal stent (LAMS) or dedicated SEMS in EUS-guided gallbladder drainage (EUS-GBD), given their enhanced ease of use and safety compared with alternatives.

Weak recommendation, low quality evidence.

ESGE suggests performing transduodenal EUS-GBD with a LAMS, rather than using the transgastric route, as this may reduce the risk of stent dysfunction.

Weak recommendation, low quality evidence.

The initial studies in the management of acute cholecystitis using EUS-GBD used fully or partially covered SEMS and plastic stents, and showed high clinical success rates [88]. However, plastic stents were associated with higher AE rates when compared with the placement of LAMSs, and both stent types required more procedural steps [88].

EUS-GBD using LAMSs was derived from EUS-guided drainage of pancreatic fluid collections and EUS-CDS [90–95]. The gallbladder is located, either from the distal stomach or duodenal bulb, using EUS, and an FNA needle (either 22G or 19G) can then be used to aspirate gallbladder content, inject contrast to fluoroscopically define the anatomy, and to introduce a 0.025-inch or 0.035-inch guidewire, over which the LAMS will be placed [85,96–99]. More commonly, an EC-LAMS is placed using the “free-hand” technique in one single step (►Fig. 1g), which has been reported to reduce the procedural time [85,96,100,101]. It is imperative to ensure that the distal flange is sufficiently pulled back to approximate the gallbladder wall against the duodenal or gastric wall before slowly releasing the stent.
With both techniques, care should be taken to adjust the puncture distance to the LAMS saddle length, which in most cases should not exceed 15 mm and preferably be as short as possible (▶Table 1). In the exceptional case where the puncture distance exceeds 15 mm and EUS-GBD is deemed necessary, the gallbladder lumen may be filled with saline or placement of a covered SEMS may be considered. Alternatively, given the increased potential risk of misplacement, the procedure may be aborted, with the patient referred for percutaneous drainage.

Transduodenal access is usually preferred over transgastric EUS-GBD, as antral LAMS placement has been associated with more symptom recurrence owing to food impaction and a higher risk of a buried LAMS [96, 98, 100]. Notably, no head-to-head comparisons have been performed between the two EUS-GBD drainage routes, with placement often governed by the most stable echoendoscope position.

Patient-related factors, such as the interposition of vessels, malignant duodenal obstruction, more optimal apposition, or even improved ergonomics for the endoscopist, can be valid reasons to settle for transgastric LAMS placement [102].

5.1.2 LAMS diameter

Several landmark papers have based their selection of LAMS diameter on the size of the gallbladder stones to allow for stone evacuation following placement: when stones are smaller than 10 mm, a 10-mm LAMS would suffice; when stones are larger than 10 mm, a 15-mm LAMS, but no larger, should be considered [84, 85, 103]. When the gallbladder is not sufficiently dilated or is filled with multiple large stones, it may not be feasible to safely deploy a 15-mm LAMS. In these cases, a smaller caliber LAMS should be placed to resolve cholecystitis. When it is not feasible to place a LAMS because of stones that would prohibit deployment, the gallbladder can be punctured with a 19G FNA needle and filled with saline in order to induce sufficient distension to facilitate stent deployment.

Regardless of the stone size, some patients with a longer expected survival time may benefit from re-intervention aimed at treating residual stones [92, 96, 104]. Clearing gallbladder stones, with or without the use of lithotripsy, and replacing the LAMS with DPPSs may potentially prevent LAMS-related AEs and preclude future biliary events. In this specific context, a 15-mm LAMS, as opposed to a 10-mm LAMS, will more readily accommodate transluminal endoscopic re-interventions.
Some patients are at increased risk of LAMS obstruction. This is especially the case in patients with a high stone burden or who have had a LAMS inserted through the stomach, where food impaction may lead to an increased risk of stent dysfunction [96, 98]. In these situations, coaxial placement of DPPSs may be considered to prevent stent occlusion by stones or food debris. Few efficacy data are currently available to systematically support this approach [85, 98, 99].

5.1.4 Stone clearance and LAMS replacement

**RECOMMENDATION**
ESGE suggests considering complete stone clearance and LAMS exchange for double-pigtail plastic stents when long-term drainage is required after EUS-guided gallbladder drainage.
Weak recommendation, low quality evidence.

Gallbladder stones may persist in almost half of cases following EUS-GBD [96]. Peroral cholecystoscopy through the LAMS provides the unique opportunity to evaluate the luminal surface of the gallbladder and permits complete stone clearance, potentially reducing future biliary events in patients who require prolonged gallbladder drainage [92, 96, 104]. These procedures can be performed as soon as 1–2 weeks after LAMS placement, although most data suggest that postponing stent removal to 4 weeks may be ideal [85, 92, 96]. Access through the EUS-GBD tract may sometimes require LAMS removal, with or without balloon dilation of the fistulous tract, to facilitate passage of the devices to aid in stone removal. Various endoscopic devices can be introduced to retrieve stones, ranging from a basket to tripods [103]. In some instances, multiple lithotripsy sessions may be required to achieve complete stone clearance.

Limited data exist regarding the long-term efficacy and safety of EUS-GBD with a LAMS. Consequently, several authors have suggested that LAMSs should be exchanged after stone removal and replaced with a DPPS (7–10 Fr), provided that there is enough residual gallbladder lumen to accommodate these stents [85, 92, 96, 99, 104].

In patients with a limited expected survival time or advanced malignant disease, EUS-GBD can be used as a definitive therapy without further surveillance. To date, no comparative studies have been performed to compare the outcomes between these different approaches.

5.2 Key question 8: What are the adverse events and possible rescue procedures in EUS-GBD?

Overall AEs following EUS-GBD vary, with most studies reporting rates between 8% and 18% [83, 94, 97, 105]. Bleeding, stent migration, capnoperitoneum, and stent occlusion with recurrent cholecystitis represent the most frequent AEs following EUS-GBD [83, 94, 97].

Recurrent cholecystitis has been reported in up to 8% of cases following LAMS placement and is mostly related to either LAMS obstruction or a “buried” LAMS [106]. The risk may be reduced by intraduodenal LAMS placement, use of coaxial DPPSs, and/or planned re-interventions with stone clearance [85, 92, 96, 99, 104].

Intraprocedural bleeding near the puncture site is generally minimized by tamponade from the LAMS. Extraluminal bleeding due to trauma to the cystic artery is rare, but requires embolization [97].

Other AEs associated with maldeployment that may occur include perforation, bile leak, and peritonitis, all of which may require urgent surgery [93, 94, 106–110]. If only the gastric or duodenal wall is perforated and the gallbladder is still intact, immediate endoscopic closure with an over-the-scope (OTS) clip can be considered. If endoscopic salvage has been successfully performed, capnoperitoneum can usually be treated conservatively, but transabdominal needle decompression may be required in cases of tension capnoperitoneum [111].

If stent deployment fails after the gallbladder has already been punctured by a LAMS, it will be imperative to proceed to either emergency percutaneous gallbladder drainage or surgery as bile leakage is inevitable and may result in potentially fatal peritonitis.

6 Gastrointestinal anastomoses

EUS-guided gastroenterostomy (EUS-GE) is used in the management of gastric outlet obstruction (GOO) and afferent loop syndrome [1]. The next sections provide guidance on how EUS-GE procedures should be performed. EUS-guided gastrogastrotomy has also been developed to facilitate ERCP in the setting of Roux-en-Y gastric bypass (RYGB), commonly referred to as the EDGE procedure (EUS-directed transgastric ERCP).

6.1 Key question 9: How should EUS-GE procedures be performed?

6.1.1 General principles for the creation of EUS-GE anastomoses

There are currently no definitive guidelines nor consensus on the preprocedural management of patients undergoing EUS-guided lumen-to-lumen anastomoses. However, similarly to other endoscopic procedures in patients with GOO, the following preprocedural precautions would apply. Patients should be kept on a clear liquid diet for a few days before the procedure and “nil per mouth” 24 hours before performing EUS-GE, to minimize the presence of residual gastric content and the risk of aspiration. A large-bore nasogastric tube may be needed to...
clear the stomach contents in some patients with persistent vomiting despite being maintained on a clear fluid diet. Post-procedurally, patients should ideally be hospitalized overnight for observation, even though there is currently no consensus; in some high volume centers, patients with no post-procedural abdominal pain are discharged the same day. Some experts advise 24 hours of fasting before initiating a clear liquid diet. In the days following the procedure, this can be slowly broadened as tolerated up to a normal diet [112]. In some centers, in the absence of pain, fluid intake is permitted within hours after the procedure, and rapidly escalated to a liquid and soft low-fiber diet thereafter. With the availability of the 20-mm LAMS, most patients may ultimately return to normal diets. The routine use of proton pump inhibitors in these patients is not supported by any evidence.

**RECOMMENDATION**

ESGE recommends using saline instillation for small-bowel distension during EUS-guided gastroenterostomy. Strong recommendation, low quality evidence.

Various techniques have been developed to create an EUS-GE aimed at overcoming two main difficulties: (i) locating the segment distal to the GOO; (ii) stabilizing the targeted loop for subsequent puncture and stent introduction. A crucial step in the successful performance of EUS-GE is providing sufficient dilation of the target loop. A nasojejunal feeding tube or nasobiliary catheter that contains more side holes and infuses larger volumes of saline is placed across the stricture beyond the ligament of Treitz over a previously placed guidewire. Alternatively, saline is instilled into the small bowel directly through the endoscope by placing it at the level of the stricture [113]. For either the catheter- or endoscope-based technique, saline is instilled using prefilled syringes or a waterjet. Dye can be added to the mixture (most often methylene blue or indigo carmine) to allow for visual confirmation of successful LAMS placement when the proximal flange opens into the stomach. Furthermore, contrast can be mixed with saline in order to fluoroscopically depict the small-bowel anatomy. In general, 250–500 mL of saline is needed to achieve sufficient distension of the target segment, although this may vary. Intravenous administration of antitmotility agents, such as butyl scopolamine or glucagon (0.5–3.0 mg), can be considered to decrease intestinal contractions.

### 6.1.2 Direct EUS-GE technique

**RECOMMENDATIONS**

ESGE recommends the use of electrocautery-enhanced LAMSs in EUS-guided gastroenterostomy. Strong recommendation, low quality evidence.

ESGE recommends the use of LAMSs of at least 15 mm in diameter in EUS-guided gastroenterostomy. Strong recommendation, low quality evidence.

A linear echoendoscope is introduced and positioned under fluoroscopic and EUS guidance to visualize the intended small-bowel loop. A transgastric puncture is performed with a 19G FNA needle and the small-bowel loop is filled with saline mixed with contrast. The endoscopist can then proceed with placement of a guidewire through the FNA needle, over which the electrocautery tip of the LAMS is advanced into the jejunum, using the Autocut setting. Alternatively, the FNA needle can be removed and the electrocautery-tipped delivery device (Autocut 100–150 W, effect 3–5) can be advanced into the jejunum using the “free-hand” technique (Fig. 1h). LAMS insertion over the wire has mostly been abandoned as this may push the jejunum further away, which may lead to stent mal-deployment. Should the endoscopist still elect to perform over-the-wire placement, we advise slow withdrawal of the guidewire when advancing the EC-LAMS to minimize displacement of the jejunum. After the delivery device is confirmed to be inside the lumen of the jejunum on EUS, the distal flange is deployed. The device is then gently retracted, approximating the small-bowel wall to the gastric wall before releasing the proximal flange under EUS or endoscopic control.

### 6.1.3 Wireless endoscopic simplified technique

After the small bowel distal to the GOO has been filled with saline, a linear echoendoscope is advanced into the stomach. After the saline filled duodenum/jejunum has been located, the electrocautery tip is advanced directly using a free-hand technique into the targeted small-bowel lumen under EUS control, without the aid of an FNA needle or guidewire (Fig. 1h). The same deployment steps described above are followed to release the stent [112, 114].

### 6.1.4 Assisted EUS-GE techniques

Assisted EUS-GE techniques refer to approaches using dilation balloons or double-balloon devices that are inserted through a gastroscope or enteroscope (e.g. endoscopic ultrasound-guided double-balloon-occluded gastroenterostomy bypass; EPASS) [115–117]. In the balloon-assisted technique, a guidewire is inserted across the GOO and the balloon catheter is advanced under fluoroscopic guidance into the jejunum. Under EUS guidance, the fluid-filled balloon or occluded jejunal segment is punctured with a 19G FNA needle and a guidewire is advanced into the jejunal lumen. A LAMS is then inserted and deployed over the guidewire.
6.1.5 What size LAMS should be used to create an EUS-GE?
For EUS-GE, both 15-mm and 20-mm LAMSs have been used. The diameter of surgically created gastroenterostomies ranges between 25 and 35 mm. Therefore, from a theoretical standpoint, a 20-mm LAMS should be preferred. Comparative data are limited, although a recent retrospective study demonstrated improved clinical efficacy with 20-mm stents compared with 15-mm stents [112].

6.2 Key question 10: How should EDGE procedures be performed?
EUS-directed transgastric ERCP (EDGE) can be offered to patients with RYGB in expert centers in an attempt to overcome the invasiveness of laparoscopy-assisted ERCP and the limitations of enteroscopy-assisted ERCP [1]. This section is aimed at providing technical guidance regarding EDGE, the timing of subsequent ERCP, and management following successful therapy.

6.2.1 What is the optimal technique to perform an EDGE procedure?
In 2011, prior to the development of LAMSs, a percutaneous approach was developed using insufflation of the gastric remnant via a 19 G needle, followed by subsequent placement of a 16-Fr PEG gastrostomy. Through this percutaneous route, ERCP could be performed [118–120]. This first attempt provided the basis for the subsequent development of a completely endoscopic approach.

The advent of LAMSs has led to the development of an endoscopic technique to join the excluded stomach to the gastric pouch, with the formation of a stable anastomosis, under EUS guidance. This creates a conduit through which a duodenoscope can be inserted [121]. Once the excluded stomach has been located by the echoendoscope positioned in the pouch or proximal jejunum, a 19G needle is advanced and 250–500 mL of saline, with or without dye, is instilled, until the excluded stomach is adequately distended. The needle is then retracted and the EC-LAMS is advanced into the excluded stomach lumen under sonographic control. Although an over-the-wire placement has been reported, the “free-hand” technique is nowadays mostly employed and the stent is released in the same way as for EUS-GE (Fig. 11) [122–124]. Care should be taken not to deploy the LAMS too caudally in the antrum or distal gastric body, as this may complicate subsequent insertion of the duodenoscope.

6.2.2 Is there a preference for LAMS diameter?

**RECOMMENDATION**
ESGE recommends the use of either 15- or 20-mm LAMSs for EDGE, with a preference for 20-mm LAMSs when considering a same-session ERCP.
Strong recommendation, low quality evidence.

In a recent large multicenter retrospective analysis of 178 EDGE procedures, the use of a smaller caliber 15-mm LAMS was an independent risk factor for intraprocedural stent dislodgement [125]. Placement of a 20-mm stent is therefore preferred as it provides easier access for the duodenoscope into the gastric remnant, which decreases the risk of stent migration. Placement of a 20-mm LAMS is strongly advised when a same-session ERCP is considered, with balloon dilation to facilitate safe passage of the duodenoscope through the stent.

6.2.3 What is the optimal time that should be allowed before performing an ERCP following LAMS placement?

**RECOMMENDATION**
ESGE suggests considering a delay of at least 7 days before performing ERCP following EDGE whenever possible.
Weak recommendation, low quality evidence.

In early 2021, a systematic review showed that intraprocedural stent migration occurred in 16% of EDGE procedures and was mainly due to stent dislodgement when a same-session ERCP was performed [126]. A recent study suggested that large caliber 20-mm LAMSs and stent fixation techniques may allow for safe same-session ERCP compared to smaller 15-mm stents [127]. When permitted, a low risk strategy can be adopted by delaying ERCP for up to 7 days following LAMS placement, which allows the gastrogastrostomy LAMS to fully expand and the fistulous tract to mature. However, for patients with cholangitis or in other urgent settings, a same-session ERCP should always be considered. This can be accomplished by adequate balloon dilation at least up to 15 mm to allow the duodenoscope to be carefully manipulated through the LAMS. Overdilation of the stent should however be avoided. Anchoring techniques, such as clipping or suturing, have also been reported to prevent migration when same-session ERCP is required [125, 128], although a recent large retrospective analysis did not identify fixation techniques as beneficial in preventing this AE [127].
LAMSs should be removed when no additional re-interventions are required, although some patients may benefit from leaving the stent for longer periods. Many methods have been described to close the gastrogastric or jejunogastric fistulous tract, although various studies suggest that these tracts may spontaneously close in most cases. Wang and colleagues proposed the technique of “spontaneous closure guided by double-pigtail plastic stents,” with an efficiency of more than 70% [129], whilst James and co-workers applied APC to the margins of the fistula tract in order to promote re-epithelialization and closure [130]. In their study, 61% of fistulas “spontaneously” closed thereafter. Some authors propose suturing or APC followed by OTS clip placement in cases of failed closure. Kedia et al. used an OTS clip system to close the gastrogastric or jejunogastric fistula after removal of the LAMS, although this may seldom be required [121].

LAMSs should be removed as soon as it becomes apparent that no additional pancreaticobiliary interventions will be required. Practices around the world are diverse, varying from systematic follow-up by upper GI series 8 weeks after LAMS removal, to immediate closure, to no follow-up or closure only in cases of failed closure. LAMSs should be removed when no additional pancreaticobiliary interventions are required within the first 7 days of placement and thereafter only when no additional pancreaticobiliary interventions are required. Strong recommendation, low quality evidence.

### 6.2.4 When should the LAMS be removed and should endoscopic closure be provided?

**RECOMMENDATION**

ESGE recommends that LAMSs should not be removed within the first 7 days of placement and thereafter only when no additional pancreaticobiliary interventions are required. Strong recommendation, low quality evidence.

Table 3: Circumstances when a high index of suspicion for stent maldeployment should be considered.

| 1 | Appearance of pneumoperitoneum on fluoroscopy immediately after distal flange deployment |
| 2 | Failure of the distal flange to anchor to the small bowel or excluded stomach, with it being impossible to advance a guidewire into its lumen (guidewire appearing extraluminal and intraperitoneal on fluoroscopy) |
| 3 | No evidence of previously infused blue-tinged fluid flowing into the stomach after full deployment of the stent |
| 4 | Lack of visualization of the target luminal structure through the stent on the contralateral side after balloon dilation of the central part of the LAMS |
| 5 | Endoscopic visualization of the peritoneum through the LAMS |

LAMS, lumen-apposing metal stent.

Table 4: Steps that can be performed for endoscopic management of intra procedural stent dislodgement.

| 1 | Maintain the guidewire in the gastric remnant with over-the-wire exchange of the duodenoscope/echoendoscope with a therapeutic gastroscope |
| 2 | Perform complete LAMS dilation, if not performed before |
| 3 | In cases with complete LAMS dislodgement, the LAMS should be removed |
| 4 | In cases with incomplete LAMS dislodgement, an attempt should be made to reposition the misdeployed flange using a grasping forceps, which can be highly effective when there is a mature anastomotic tract |
| 5 | In cases with LAMS misdeployment, insert (through the previously positioned LAMS, if still in place) a fully covered esophageal stent or a new LAMS of the same or larger size to bridge both wall defects; this can be further secured by placing double-pigtail plastic stents through it |
| 6 | When the guidewire is lost, enter the peritoneal cavity with a therapeutic gastroscopy and search for the excluded stomach perforation. Once detected, a transfistula guidewire should be inserted, followed by NOTES techniques to complete the procedure, as highlighted for stent maldeployment cases |
| 7 | Fluoroscopic confirmation of the absence of a leak should be obtained at the end of the procedure |

LAMS, lumen-apposing metal stent; NOTES, natural orifice transluminal endoscopic surgery.

### 6.3 Key question 11: What are the adverse events and possible rescue procedures in EUS-guided gastrointestinal anastomoses?

#### 6.3.1 Stent maldeployment

LAMS maldeployment can be decreased by careful patient selection and use of proper endoscopic techniques [5,28,131–137]. In the largest available retrospective study on EUS-GE, performed in 16 expert centers, distal or proximal LAMS flange maldeployment occurred in 44 out of 467 patients (9.4%) [138]. This AE was endoscopically managed in the majority of cases, with success largely dependent on its immediate recognition during the procedure. Indeed, surgery was required in only five patients (11.4%) [138]. A high index of suspicion for stent maldeployment should be considered especially under the circumstances presented in Table 3 [28]. Needle decompression of the capnoperitoneum may be necessary and systemic broad-spectrum antibiotics should be administered. In cases where the stent cannot be bridged or the defect cannot be securely closed, surgical management should be undertaken with removal of the LAMS, closure of the defect, and creation of a surgical anastomosis. This may be challenging for the surgeon in the setting of surgically altered upper GI anatomy and may require conversion to an open procedure [121,136,139,140].

Diagnostic laparoscopy may be warranted when there is doubt about puncture of the duodenum or jejunum with an EC-LAMS. Whereas closure of the stomach is usually easily man-
aged endoscopically, it is more challenging to recognize the level of a duodenal or jejunal injury. Delayed perforations at the level of the enteric access point may occur late due to thermal necrosis. In fragile patients with a short-term poor overall prognosis, stent maldeployment may be fatal, even if salvaged endoscopically [141].

Maldeployment of a stent into the colon is usually recognized late, after the patient has developed diarrhea associated with meals. Surgery is generally not required, as simple stent removal and endoscopic fistula tract closure may be performed once the fistula and anastomotic tract have matured (typically after 7 days or more).

With EDGE, intraprocedural LAMS dislodgement is a common AE, almost entirely related to same-session ERCP. Its severity is related to the lack of a mature fistulous tract, which results, if not recognized, in free perforation. Most cases can be managed endoscopically as long as guidewire access to the remnant stomach is preserved [121].

The endoscopic actions presented in Table 4 may be useful to salvage a situation where maldeployment has occurred [121, 123, 126, 129, 142–146]. There are a few reports where perforation could not be managed endoscopically and surgical repair was necessary, with no related fatalities reported thus far [121, 126, 142, 144, 146, 147].

6.3.2 Management of intra- and post-procedural bleeding
Intra- or post-procedural hemorrhage is a rare AE encountered in EUS-guided lumen-to-lumen anastomoses. It can be a direct consequence of: (i) fistula creation [148], (ii) LAMS balloon dilation [149], or (iii) LAMS-induced ulcer or erosion of the GI tract mucosa [139, 149, 150]. For the latter, standard endoscopic hemostatic techniques are usually highly effective, in association with proton pump inhibitor administration. Rarely, LAMS removal or exchange is needed. Intraprocedural bleeding following LAMS dilation can be successfully treated by balloon tamponade or through-the-scope SEMS placement to compress the bleeding vessel [151]. When conservative measures fail, especially in cases of extraluminal bleeding, emergent angiography with vessel embolization is usually effective, while surgical exploration is rarely needed.

6.3.3 Endoscopic treatment of long-term adverse events

**RECOMMENDATION**

ESGE suggests long-term clinical follow-up and/or intermittent stent surveillance, with or without stent exchange, after EUS-guided gastroenterostomy for benign disease.

Weak recommendation, low quality evidence.

Long-term AEs in EUS-guided lumen-to-lumen anastomoses include stent migration [126, 142, 149], obstruction by food residue [149], and tissue ingrowth [150] or overgrowth [140]. Recurrence of GOO symptoms, requiring a repeat procedure, occurs in 9%-11.4% of EUS-GE procedures [152, 153]. However, long-term data on procedural outcomes beyond several months are scanty, which is an important consideration, especially in the management of benign GOO [154]. Cases of stent obstruction can be managed by endoscopic clearance of debris/food, by stent removal and replacement, or by insertion of a second stent bridging the initially placed LAMS [140, 149].

In patients with benign GOO, LAMS removal should be considered if the initial obstruction has resolved, as proven by upper GI series or cross-sectional imaging studies. Otherwise, clinical follow-up or intermittent stent surveillance (with or without exchange) should be performed at regular intervals [149]. For most malignant indications, stents should be left in place indefinitely, as stenosis/closure of the anastomotic tract would likely occur after stent removal [155].

**Disclaimer**

The legal disclaimer for ESGE guidelines [156] applies to this technical review.

**Acknowledgements**

The authors would like to sincerely thank Professor Marianna Arvanitakis, Hôpital Erasme Brussels, and Professor Takao Itoi, Tokyo Medical University, for their review of this manuscript. The authors are furthermore grateful for the valuable comments provided by Dr. Huseyin Ataseven (Necmettin Erbakan University, Konya, Turkey) on behalf of the Turkish Society of Gastroenterology, Dr. Rodica Gincul on behalf of the French Society of Digestive Endoscopy, Prof. Frédéric Prat (Université de Paris et Inserm U1016, France), and Dr. Rogier Vooromers (Amsterdam UMC, The Netherlands). The authors would also like to acknowledge Martha Meisen for providing the illustrations.

**Competing interests**

M. Barthet has received a research grant from Boston Scientific (2015 to present). K.F. Binmoeller has received fees for training and education from Boston Scientific (2015 to present). M. Bronswijk has consultancy agreements with Prion Medical and Taewoong Medical (both ongoing). M.A. Khashab receives consultancy fees from BSCI, Medtronic, Olympus, Pentax, GI Supply, and Apollo (all ongoing). A. Larghi has received consultancy fees from Boston Scientific and Pentax Medical, and educational fees from Taewoong Medical; he receives research support from Medtronic. R. Law receives consultancy fees from Medtronic (2020 to present) and Conmed (2021). M. Perez-Miranda receives consultancy fees from Lumendi and Olympus (both 2020 to present) and consultancy and speaker’s fees from Boston Scientific (2021). S. van der Merwe has received consultancy fees from Boston Scientific and Cook Endoscopy (both 2012 to present); he was the Boston Chair in Interventional Endoscopy (2018 to 2021) and is the Cook Chair in Portal Hypertension (2021). J.E. van Hooft has received lecture fees from Medtronics (2014, 2015, and 2019), Cook Medical (2019), and Abbvie (2021), and consultancy fees from Boston Scientific (2014 to 2017) and Olympus (2021); her department received research support from Abbott (2014 to 2017) and Cook Medical (2014 to 2019). P.G. Arcidiacono, A. Badauoi, S. Everett, T. Hucl, R. Kunda, S. Lakhatakia, M. Rimbas, and R.L.J. van Wanrooij declare that they have no conflict of interest.
References


[59] van Geenen EJM, Siersema PD. Stent migration into the abdominal cavity after EUS-guided hepaticogastrostomy. Gastrointest Endosc 2018; 87: 617–618


[134] Irani S, Khashab M. Gastric outlet obstruction: when you cannot do an endoscopic gastroenterostomy or enteral stent, try an endoscopic duodenojejunostomy or jejunoojejunostomy. VideoGIE 2020; 5: 125–128


[139] Chen YI, Itoi T, Baron TH et al. EUS-guided gastroenterostomy is comparable to enteral stenting with fewer re-interventions in malignant gastric outlet obstruction. Surg Endosc 2017; 31: 2946–2952

[140] Chen YI, Kunda R, Storm AC et al. EUS-guided gastroenterostomy: a multicenter study comparing the direct and balloon-assisted techniques. Gastrointest Endosc 2018; 87: 1215–1221